Health
AUSTRALIAN CANCER SPECIALISTS May Hold Key To Next Advancement In Ovarian Cancer
At The Forefront Of A Drug Trial
(Source: Novogen Limited)
(Source: Novogen Limited)
Three Leading Australian Cancer Treatment Centres are at the forefront of a Drug Trial that could see the Next Major Advancement in Ovarian Cancer Therapy. Associate Professor Jim Coward, an Oncologist at Icon Cancer Care in South Brisbane, is Leading the First Clinical Trial of Cantrixil, a Locally Developed Molecule by Biotech Novogen that could enable Intraperitoneal (IP) Chemotherapy to again become a Viable Treatment Option in Patients where it has become ineffective due to resistance.
Flinders Medical Centre in South Australia and Westmead Hospital in Sydney are also participating, along with Leading US Hospitals Peggy and Charles Stephenson Cancer Centre, and Mary Crowley Cancer Research Centre. The Phase 1 trial, which is designed to Understand the Safety Profile of Cantrixil in Human Subjects and establish a Maximum Tolerated Dose (MTD) for the Drug, commenced in December 2016 and Preliminary Results are expected as early as Next Year.
Ovarian Cancer is the Eighth Most Common Cancer in Women, and the Sixth Most Common cause of Cancer Death for Women in Australia. The Australian Institute of Health and Welfare estimates that in 2017, 1580 new cases will be diagnosed and 1047 Women will die from Ovarian Cancer.
Ovarian Cancer is the Eighth Most Common Cancer in Women, and the Sixth Most Common cause of Cancer Death for Women in Australia. The Australian Institute of Health and Welfare estimates that in 2017, 1580 new cases will be diagnosed and 1047 Women will die from Ovarian Cancer.
Recurrent, Chemo-Resistant Ovarian Cancer is thought to be due to a Subgroup of Slow-Growing, Drug Resistant Cancer Cells with Stem-Like Properties and a High Capacity for Tumour Repair. These are often referred to as Tumour-Initiating Cells or 'Cancer Stem Cells'.
Women interested in participating should discuss the Cantrixil Trial with their Oncologist.
Source : Novogen Limited
Ruby BIRD
http://www.portfolio.uspa24.com/
Yasmina BEDDOU
http://www.yasmina-beddou.uspa24.com/
Women interested in participating should discuss the Cantrixil Trial with their Oncologist.
Source : Novogen Limited
Ruby BIRD
http://www.portfolio.uspa24.com/
Yasmina BEDDOU
http://www.yasmina-beddou.uspa24.com/
Ruby Bird Yasmina Beddou Advancement Australian Cancer Specialists Therapy Ovarian Cancer Forefront Of A Drug Trial Icon Cancer Care In South Brisbane
Liability for this article lies with the author, who also holds the copyright. Editorial content from USPA may be quoted on other websites as long as the quote comprises no more than 5% of the entire text, is marked as such and the source is named (via hyperlink).
